Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake

Rosário, Pedro Weslley; Reis, Janice Sepúlveda; Barroso, Álvaro Luís; Rezende, Leonardo Lamego; Padrão, Eduardo L.; Fagundes, Tales Alvarenga

doi:10.1097/00006231-200411000-00002

Cited by 52 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Activities between 30 and 100 mCi of 131 I generally show similar rates of successful remnant ablation (154)(155)(156)(157), although there is a trend toward higher success rates with higher activities (158).…”

Section: What Activity Of 131 I Should Be Used For Remnant Ablation?mentioning

confidence: 99%

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

Cooper

Doherty

Haugen

et al. 2006

Thyroid

1,893

932

View full text Add to dashboard Cite

Section: What Activity Of 131 I Should Be Used For Remnant Ablation?mentioning

confidence: 99%

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

Cooper

Doherty

Haugen

et al. 2006

Thyroid

1,893

932

View full text Add to dashboard Cite

“…In the remainder of patients, recombinant TSH is recommended whenever it is available (Recommendation A). In patients with low risk of persistent or recurrent disease and in whom a total thyroidectomy was properly performed, an activity of 30 mCi of 131 I is efficacious to achieve remnant ablation (108,109,(115)(116)(117)(118) and exhibits low medium-and long-term relapse rates (67,93,117,119). In this regard, two major randomized trials with 438 (108) and 756 (109) patients stand out.…”

Section: Recommendation 37mentioning

confidence: 99%

“…Both studies showed clearly that the efficacy of 30 mCi for the purpose of ablation was the same compared to 100 mCi independent of the pre-treatment, i.e., discontinuation of T4 or recombinant TSH (108,109). When the size of the thyroid remnant is uncertain, the parameters to indicate an activity of 30 mCi are the volume measured on US (≤ 2 g), thyroid bed uptake [≤ 2% (108,109,115)], or postoperative Tg levels (97).…”

Section: Recommendation 37mentioning

confidence: 99%

Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus

Rosário

Ward

Carvalho

et al. 2013

Arq Bras Endocrinol Metab

115

121

View full text Add to dashboard Cite

Thyroid nodules are frequent findings, especially when sensitive imaging methods are used. Although thyroid cancer is relatively rare, its incidence is increasing, particularly in terms of small tumors, which have an uncertain clinical relevance. Most patients with differentiated thyroid cancer exhibit satisfactory clinical outcomes when treatment is appropriate, and their mortality rate is similar to that of the overall population. However, relapse occurs in a considerable fraction of these patients, and some patients stop responding to conventional treatment and eventually die from their disease. Therefore, the challenge is how to identify the individuals who require more aggressive disease management while sparing the majority of patients from unnecessary treatments and procedures. We have updated the Brazilian Consensus that was published in 2007, emphasizing the diagnostic and therapeutic advances that the participants, representing several Brazilian university centers, consider most relevant in clinical practice. The formulation of the present guidelines was based on the participants' experience and a review of the relevant literature. Arq Bras Endocrinol Metab. 2013;57(4):240-64 Keywords Thyroid nodules; thyroid cancer; Brazilian consensus; update RESUMO Nódulos tireoidianos são muito frequentes, sobretudo quando se empregam métodos sensí-veis de imagem. Embora o câncer seja proporcionalmente raro, sua incidência vem aumentando, especialmente de tumores pequenos, cuja evolução clínica é incerta. A maioria dos pacientes com carcinoma diferenciado de tireoide evolui bem quando adequadamente tratada, com índices de mortalidade similares à população geral. Por outro lado, um percentual não desprezível apresenta recidivas e alguns eventualmente não respondem às terapias convencionais, evoluindo para óbito. Assim, o desafio é distinguir os pacientes merecedores de condutas mais agressivas e, ao mesmo tempo e não menos importante, poupar a maioria de tratamentos e procedimentos desnecessários. Atualizamos o Consenso Brasileiro publicado em 2007, ressaltando os avanços diagnósticos e terapêuticos que os participantes, de diferentes Centros Universitários do Brasil, consideram mais relevantes para prática clínica. A elaboração dessas diretrizes foi baseada na experiência dos participantes e revisão da literatura pertinente. Arq Bras Endocrinol Metab. 2013;57(4):240-64 Descritores

show abstract

“…Radioablation of thyroid remnants after thyroid hormone withdrawal can be accomplished in most instances by a single 131 I dose of 30 mCi, which delivers to the patient about 10 whole body rads (27,28). A dose of 100 mCi 131 I is more certain to provide ablation with a single administration than smaller doses, at the expense, however, of higher radiation exposure to the patient (29,30).…”

Section: Postoperative Radioiodine Administrationmentioning

confidence: 99%

Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer

Pitoia

Ward

Wohllk

et al. 2009

Arq Bras Endocrinol Metab

121

View full text Add to dashboard Cite

The aims of these recommendations were to develop clinical guidelines for evaluation and management of patients with differentiated thyroid cancer applicable to Latin American countries. The panel was composed by 13 members of the Latin American Thyroid Society (LATS) involved with research and management of thyroid cancer from different medical centers in Latin America. The recommendations were produced on the basis of the expert opinion of the panel with use of principles of Evidence-Based Medicine. Following a group meeting, a first draft based on evidences and the expert opinions of the panel was elaborated and, later, circulated among panel members, for further revision. After, this document was submitted to the LATS members, for commentaries and considerations, and, finally, revised and refined by the authors. The final recommendations presented in this paper represent the state of the art on management of differentiated thyroid cancer applied to all Latin American countries. Arq Bras Endocrinol Metab. 2009;53(7):884-97. KeywordśThyroid cancer; thyroid ultrasonography; radioiodine therapy; thyroglobulin; consensus RESUMO Estas recomendações tiveram por objetivo o desenvolvimento de diretrizes para avaliação e manejo de pacientes com câncer diferenciado da tiroide em países latino-americanos. Um painel composto por 13 membros da Sociedade Latino-Americana de Tireoide (SLAT) -que estavam envolvidos em pesquisas, e eram peritos no cuidado do paciente com câncer da tiroide e provenientes de diferentes centros médicos latino-americanos -utilizou os princípios da Medicina Baseada em Evidências para produzir esse consenso. Após uma primeira reunião, um texto inicial foi elaborado, baseado em evidências e opiniões dos especialistas do painel e, posteriormente, circulado entre os membros do painel, para revisão. Após a revisão, o documento foi enviado aos membros da SLAT para comentários e considerações e, finalmente, revisado e refinado pelos autores. As recomendações finais aqui apresentadas demonstram o estado da arte no manejo do câncer diferenciado da tireoide aplicadas aos países latino-americanos.Arq InTRODUCTIOn T he risk of malignancy in a thyroid nodule varies between 5% and 10% in iodine sufficient countries, and the amount of iodine supplemented in table salt influences on the morphology of the malignant tumor types (1).

show abstract

Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake

Cited by 52 publications

References 24 publications

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus

Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer

Contact Info

Product

Resources

About